| Companies sponsors |
Roche (Atezolizumab with gemcitabine and carboplatin) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
NHS Greater Preston CCG |
| |
NHS Hartlepool and Stockton-on-Tees CCG |
| |
Welsh Government |
| Patient carer groups |
Action Bladder Cancer UK |
| |
Black Health Agency for Equality |
| |
Bladder and Bowel Community |
| |
Bladder and Bowel UK |
| |
Cancer 52 |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Fight Bladder Cancer |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
Pelican Cancer Foundation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| Professional groups |
Association of Cancer Physicians |
| |
British Association of Urological Nurses |
| |
British Association of Urological Surgeons |
| |
British Geriatrics Society |
| |
British Gynaecological Cancer Society |
| |
British Institute of Radiology |
| |
British Psychosocial Oncology Society |
| |
British Society of Urogenital Radiology |
| |
British Society of Urogynaecology |
| |
British Uro-Oncology Group |
| |
Cancer Research UK |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiographers |
| |
UK Clinical Pharmacy Association |
| |
UK Oncology Nursing Society |
| |
Urology Foundation |
| Associated guideline groups |
National Guideline Centre |
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Accord Healthcare (carboplatin, cisplatin, doxorubicin, gemcitabine, methotrexate) |
| |
Allergan (gemcitabine) |
| |
Amgen (pegfilgrastim) |
| |
Chugai Pharma (lenograstim) |
| |
Concordia International (methotrexate) |
| |
Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine) |
| |
Janssen-Cilag (doxorubicin) |
| |
Lilly UK (gemcitabine) |
| |
Medac GmbH (doxorubicin, gemcitabine) |
| |
Merck Sharp & Dohme (pembrolizumab) |
| |
Nordic Pharma (methotrexate) |
| |
Orion Pharma (methotrexate) |
| |
Pfizer (doxorubicin, methotrexate, vinblastine) |
| |
Rosemont Pharmaceuticals (methotrexate) |
| |
Sandoz (cisplatin, methotrexate) |
| |
Seacross Pharmaceuticals (doxorubicin) |
| |
Sun Pharma (carboplatin, gemcitabine) |
| |
Teva UK (doxorubicin, lipegfilgrastim, methotrexate) |
| |
Therakind (methotrexate) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Urology |
| |
Genomics England |
| |
Institute of Cancer Research |
| |
MRC Clinical Trials Unit |
| |
National Cancer Research Institute |
| |
National Cancer Research Network |
| |
National Institute for Health Research |
| |
Leeds Institute of Cancer & Pathology |